Shares in oncology specialist Merrimack Pharmaceuticals closed 16% down on Friday after the US company announced that it was discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors.
A safety update from a Phase I study showed that, despite the trial protocol being amended, it was unable to reach optimal therapeutic index for MM-310 due to continued observation of cumulative peripheral neuropathy.
Merrimack has terminated the study and expects to initiate a workforce reduction as it closes out clinical activities, reflective of its narrowed preclinical pipeline and in line with prior cost-cutting measures
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze